Scientist writing results in lab_cropped.jpg

Published Papers

Here are published papers from Dr. Nagourney, his team here at the Nagourney Cancer Institute (formerly Rational Therapeutics) and colleagues from around the world.

Since founding Rational Therapeutics (now Nagourney Cancer Institute) over 20 years ago, Dr. Nagourney, his team and colleagues have published a number of papers supporting the use of the Ex-Vivo Analysis of Programmed Cell Death (EVA-PCD) functional profiling assay, general cancer research, and the effectiveness of new drugs and combinations.

We have selected our most recent and most prominent papers to make available for download on this site. Click on the image or title in the section below to see each published paper.

Our most recent paper (see below) released March 2019 reported that a drug commonly used to treat kidney and liver cancer was discovered effective for breast cancer, which may open new drug therapies to patients regardless of tumor type. This means that cancer drugs can be repurposed beyond known uses.


Survival Curves

Comparing the survival of patients who tested sensitive to the agents they received, compared with those who were found resistant to the treatments that they received.

Clinical Application of Assay-Directed Therapy

Predicted clinical outcomes for patients treated with agents found active in the laboratory using the EVA-PCD functional profile.

Physician Information

Find out how you can receive specific information on how your patient’s cancer cells will react to single agents, combinations or targeted therapies.